Evidence map›Paper›PMID 26456660›Full record

ArticleThe Analyst2016

Identification of a p53-based portable degron based on the MDM2-p53 binding region.

Adam T Melvin, Lukas D Dumberger, Gregery S Woss, Marcey L Waters, Nancy L Allbritton

Open access · greenAbstract read
In one paragraph

Article in The Analyst, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Degron-based bioPROTACs for controlling signaling in CAR T cells.bioRxiv : the preprint server for biology · 2024
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Adam T MelvinCain Department of Chemical Engineering, Louisiana State University, Baton Rouge, LA 70803, USA.
Lukas D DumbergerDepartment of Chemistry, University of North Carolina, Chapel Hill, NC 27599, USA. nlallbri@unc.edu.
Gregery S WossDepartment of Chemistry, University of North Carolina, Chapel Hill, NC 27599, USA. nlallbri@unc.edu.
Marcey L WatersDepartment of Chemistry, University of North Carolina, Chapel Hill, NC 27599, USA. nlallbri@unc.edu.
Nancy L AllbrittonDepartment of Chemistry, University of North Carolina, Chapel Hill, NC 27599, USA. nlallbri@unc.edu and Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC 27599, USAand North Carolina State University, Raleigh, NC 27695, USA.
University of North Carolina at Chapel Hill · USLouisiana State University · US

Funding

Single-Cell Measurement of Lipid Signaling in Colorectal CancerR01CA177993 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ALLBRITTON, NANCY L. · 2014 to 2018
$3.0M
Protectides: A tool for drug target assays in myelomaR01EB011763 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ALLBRITTON, NANCY L. · 2010 to 2013
$2.2M
Design of Degron-based Substrates Capable of E3 Ligase-mediated UbiquitinationF32CA162574 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MELVIN, ADAM THOMAS · 2011 to 2013
$110k
NCI NIH HHS F32 CA162574NCI NIH HHS F32CA162574NCI NIH HHS R01 CA177993NCI NIH HHS R01CA177993NIBIB NIH HHS R01 EB011763NIBIB NIH HHS R01EB011763
6 · The paper itself

Abstract

In recent years the ubiquitin proteasome system (UPS) has garnered increasing interest as a target for chemotherapeutics. Due to the success of the proteasome inhibitors Bortezomib and Carfilzomib in the treatment of multiple myeloma, several new compounds have been developed to target E3 ubiquitin ligases and the proteasome in numerous human cancers. This has increased the need for new analytical methods to precisely measure intracellular enzyme activity in cells. A key component of a desired analytical method is a substrate that is capable of rapid intracellular ubiquitination yet easily incorporated into the next generation of more sophisticated UPS reporters. Portable degradation sequences, or degrons, have the ability to bind to E3 ligases and promote substrate ubiquitination when the sequence is presented in isolation or appended to other entities such as fluorescent peptide-based reporters. Previous work identified an E3 ligase (MDM2)-binding element at p53 amino acids 92-112, which was later demonstrated to be rapidly ubiquitinated in cytosolic lysates effectively functioning as a transportable degron. In this work, a shortened p53 sequence within amino acids 92-112 that displayed rapid ubiquitination kinetics was identified. A nine-member peptide library was synthesized using sequence elements of various sizes and lengths, all based on the initial 22 amino acid long sequence, containing a single ubiquitination site lysine. The ubiquitination kinetics were determined using a combination of gel electrophoresis and analytical high performance liquid chromatography (HPLC) to rank the members of the library and identify the optimal ubiquitination sequence. This analysis identified the five amino acid sequence, KGSYG, corresponding to residues 105-108 with an added N-terminal lysine, as a portable degron since this sequence demonstrated the most rapid ubiquitination kinetics.

Indexed as

ProteolysisAmino Acid SequenceChromatography, High Pressure LiquidChromatography, Reverse-PhaseCytosolHeLa CellsHumansKineticsProtein BindingProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53

Identifiers

PMID26456660
PMCPMC6042837
OpenAlexW1856693873

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.